Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland 

Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has announced its upcoming presentation at the International Medical Cannabis Conference (IMCCB-25) in Bern, Switzerland, scheduled for February 13-14, 2025. The company will present new data comparing their proprietary ART12.11 tablets to Epidiolex.

Professor Saoirse O'Sullivan, Vice President Translational Science at Artelo, will deliver a presentation titled 'A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex' on February 14, 2025. The presentation will focus on recent pharmacokinetic results from canine studies comparing ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), with Epidiolex.

Artelo Biosciences specializes in modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatological or neurological conditions.

SOLANA BEACH, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it will be presenting data on ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), at the International Medical Cannabis Conference (IMCCB-25) held at the University of Bern, Switzerland February 13-14, 2025.

Professor Saoirse O’Sullivan, Vice President Translational Science at Artelo Biosciences, is scheduled to deliver a presentation entitled, “A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex” on Friday, February 14, 2025 at 12:00pm Central European Standard Time. The presentation will showcase Artelo’s recently obtained pharmacokinetic results in canine studies with the Company’s proprietary oral solid compositions of ART12.11 compared to Epidiolex.

For more information about IMCCB-25 visit https://www.imccb.org

About ART12.11

ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Significantly enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile in a solid dosage form may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The U.S. issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.

About IMCCB-25

The IMCCB-25 seeks to inform participants about the latest evidence and concepts regarding cannabis- and cannabinoid-based therapies. It aims to assist prescribers in practically implementing best practices based on current research, expert opinions and therapy guidelines. The IMCCB-25 conference covers a broad spectrum of topics, including basic and clinical methodologies, safety, analytics, pharmaceutics, regulatory and legal considerations, pharmacological insights, and technological advancements. The emphasis is on practical implications for patients, researchers, medical persons, and industry leaders alike. Additional topics include palliative care, women medicine, psychiatry and geriatric diseases, niche indications as well as non-medical cannabis use disorders. More information about IMCCB-25 can be found at https://www.imccb.org

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

FAQ

What new data will ARTL present at IMCCB-25 in February 2025?

ARTL will present pharmacokinetic study results comparing their ART12.11 tablets to Epidiolex, showing comparable pharmacokinetics based on canine studies.

How does ARTL's ART12.11 differ from Epidiolex?

ART12.11 is a proprietary cocrystal combining cannabidiol (CBD) and tetramethylpyrazine (TMP), formulated as an oral solid tablet, while Epidiolex is a liquid CBD formulation.

When and where will ARTL present their ART12.11 research findings?

ARTL will present on February 14, 2025, at 12:00pm Central European Standard Time during the IMCCB-25 conference at the University of Bern, Switzerland.

What therapeutic areas is ARTL targeting with their drug development?

ARTL is developing treatments for people living with cancer, pain, dermatological conditions, and neurological conditions through lipid-signaling pathway modulation.